A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease

Neurobiology of Aging

Volumn 28, Issue 12, 2007, Pages 1834-1839

  Selley, Michael L ^a  

^a Angiogen Pharmaceuticals Pty Ltd   (Australia)

Author keywords

Alzheimer's disease; Phospholipid; Polyunsaturated fatty acid; S Adenosylhomocysteine

Indexed keywords

DOCOSAHEXAENOIC ACID; HOMOCYSTEINE; METHYLTRANSFERASE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; POLYUNSATURATED FATTY ACID; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; BRAIN PERFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME MECHANISM; ERYTHROCYTE; FATTY ACID METABOLISM; FEMALE; HUMAN; HUMAN CELL; LIVER; MALE; METHYLATION; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; RISK FACTOR; STROKE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; S-ADENOSYLHOMOCYSTEINE; STATISTICS AS TOPIC;

EID: 35148824104     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.08.003     Document Type: Article

References (65)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. (1994), American Psychiatric Press, Washington, DC
2. Ay H., Arsava E.M., Tokgozoglu S.L., Ozer N., and Saribas O. Hyperhomocysteinemia is associated with the presence of left atrial thrombus in stroke patients with nonvalvular atrial fibrillation. Stroke 34 (2003) 909-912
3. Barberger-Gateau P., Letenneur L., Deschamps V., Pérès K., Dartigues J.F., and Renaud S. Fish, meat and risk of dementia: cohort study. BMJ 325 (2002) 932-933
4. Bostom A.G., Rosenberg I.H., Silbershatz H., Jacques P.F., Selhub J., D'Agostino R.B., et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham study. Ann Intern Med 131 (1999) 352-355
5. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43 (2004) 633-645
6. Carver J.D., Benford V.J., Han B., and Cantor A.B. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res Bull 56 (2001) 79-85
7. Castro R., Rivera I., Struys E.A., Jansen E.E.W., Ravasco P., Camilo M.E., et al. Increased homocysteine and S-adenosyhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 49 (2003) 1292-1296
8. Caudill M.A., Wang J.C., Melnyk S., Pogribny I.P., Jernigan S., Collins M.D., et al. Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl- deficient cystathionine β-synthase heterozygous mice. J Nutr 131 (2001) 2811-2818
9. Chiang P.K., Gordon R.K., Tal J., Zeng G.C., Doctor B.P., Pardhasaraadhi K., et al. S-Adenosylmethionine and methylation. FASEB J 10 (1996) 471-480
10. 12 and serum total homocysteine levels in confirmed Alzheimer's disease. Arch Neurol 55 (1998) 1449-1455
11. Conquer J.A., Tierney M.C., Zecevic J., Bettger W.J., and Fisher R.H. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia and cognitive impairment. Lipids 35 (2000) 1305-1312
12. de la Torre J.C. Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol Res 26 (2004) 517-524
13. Delion S., Chalon S., Guilloteau D., Besnard J.-C., and Durand G. α-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the frontal cortex. J Neurochem 66 (1996) 1582-1591
14. Delion S., Chalon S., Guilloteau D., Lejeune B., Besnard J.-C., and Durand G. Age-related changes in phospholipid fatty acid composition and monoaminergic neurotransmission in the hippocampus of rats fed a balanced or an n-3 polyunsaturated fatty acid-deficient diet. J Lipid Res 38 (1997) 680-689
15. Drzewoski J., Czupryniak L., Chwatko G., and Bald E. Hyperhomocysteinemia in poorly controlled type 2 diabetes patients. Diabetes Nutr Metab 13 (2000) 319-324
16. Elias M.F., Wolf P.A., D'Agostino R.B., Cobb J., and White L.R. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 138 (1993) 353-364
17. Favrelière S., Stadelmann-Ingrand S., Huguet F., De Javel D., Piriou A., Tallineau C., et al. Age-related changes in ethanolamine glycerophospholipid fatty acid levels in rat frontal cortex and hippocampus. Neurobiol Aging 21 (2000) 654-660
18. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive status of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
19. Gamoh S., Hashimoto M., Sugioka K., Shahdat Hossain M., Hata N., Misawa Y., et al. Chronic administration of docosahexaenoic acid improves reference memory-learning ability in young rats. Neuroscience 93 (1999) 237-241
20. Gamoh S., Hashimoto M., Hossain S., and Masumura S. Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin Exp Pharmacol Physiol 28 (2001) 266-270
21. Hashimoto M., Hossain S., Shimada T., Sugioka K., Yamasaki H., Fujii Y., et al. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease rat models. J Neurochem 81 (2002) 1084-1091
22. Heude B., Ducimetière P., and Berr C. Cognitive decline and fatty acid composition of erythrocyte membranes-the Eva study. Am J Clin Nutr 77 (2003) 803-808
23. Hirafuji M., Machida T., Hamaue N., and Minami M. Cardiovascular protective effects of n-3 polyunsaturated fatty acids with special emphasis on docosahexaenoic acid. J Pharmacol Sci 92 (2003) 308-316
24. Hofman H., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., et al. Atherosclerosis, apolipoprotein E and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349 (1997) 151-154
25. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 316 (1998) 894-898
26. Honig L.S., Tang M.X., Albert S., Costa R., Luchsinger J., Manly J., et al. Stroke and the risk of Alzheimer's disease. Arch Neurol 60 (2003) 1707-1712
27. Hu Y., Komoto J., Huang Y., Gomi T., Ogawa H., Takata Y., et al. Crystal structure of S-adenosylhomocysteine hydrolase from liver. Biochemistry 38 (1999) 8323-8333
28. Hultberg B., Agardh E., Andersson A., Brattstrom L., Isaksson A., Israelsson B., et al. Increased levels of plasma homocysteine are associated with neuropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 51 (1991) 277-282
29. James S.J., Melnyk S., Pogribna M., Pogribna I.P., and Caudill M.A. Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 132 (2002) 2361S-2366S
30. Kalaria R.N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 21 (2000) 321-330
31. Kalback W., Esh C., Castaño E.M., Rahman A., Kokjohn T., Luehrs D.C., et al. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res 26 (2004) 525-539
32. Kalmijn S., Launer L.J., Ott A., Witteman J.C., Hofman A., and Breteler M.M. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42 (1997) 776-782
33. Kennedy B.P., Bottiglieri T., Arning E., Ziegler M.G., Hansen L.A., and Masliah E. Elevated S-adenosyhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J Neural Transm 111 (2004) 547-567
34. Kerins D.M., Koury M.J., Capdevila A., Rana S., and Wagner C. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr 74 (2001) 723-729
35. Kivipelto M., Helkala E.-L., Laakso M.P., Hänninen T., Hallikainen M., Albanian K., et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal population based study. BMJ 322 (2001) 1447-1451
36. Korzun W.J., and Ho O.V. Stability of plasma total homocysteine concentrations in EDTA-whole blood kept on ice. Clin Lab Sci 13 (2000) 196-198
37. Kuuisto J., Koivisto K., Mykkänen L., Helkala E.-L., Vanhanen M., Kesäniemi A., et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein e4 phenotype: cross sectional population based study. BMJ 315 (1997) 1045-1049
38. Lim G.P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer model. J Neurosci 25 (2005) 3032-3040
39. Loehrer F.M.T., Tschöpl M., Angst C.P., Litynski P., Jäger K., Fowler B., et al. Disturbed ratio of erythrocyte and plasma S-adenosylmethionine/S-adenosylhomocysteine in peripheral occlusive vascular disease. Atherosclerosis 154 (2001) 147-154
40. Magera M.J., Lacey J.M., Casetta B., and Rinaldo P. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chem 45 (1999) 1517-1522
41. McCaddon A., Davies G., Hudson P., Tandy S., and Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 13 (1998) 235-239
42. McKhan G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.N. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 (1984) 939-944
43. Meigs J.B., Jacques P.F., Selhub J., Singer D.E., Natham D.M., Rifai N., et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes Care 24 (2001) 1403-1410
44. Moriguchi T., Loewke J., Garrison M., Catalan J.N., and Salem N. Reversal of docosahexaenoic acid deficiency in the rat brain, retina, liver and serum. J Lipid Res 42 (2001) 419-427
45. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Wilson R.S., et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer's disease. Arch Neurol 60 (2003) 940-946
46. Nauck M., Bisse E., Nauck M., and Wieland H. Pre-analytical conditions affecting the determination of the plasma homocysteine concentration. Clin Chem Lab Med 39 (2001) 675-680
47. Nygard O., Vollset S.E., Refsum H., Stensvold I., Tverdal A., Nordrehaug J.E., et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274 (1995) 1526-1533
48. Ott A., Breteler M.M., de Bruyne M.C., van Harskamp F., Grobbee D.E., Hofman A., et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 28 (1997) 316-321
49. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., and Bretteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53 (1999) 1937-1939
50. Richardson A.J., Allen S.J., Hajnal J.V., Cox I.J., Easton T., and Puri B.K. Associations between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosophorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes. Prog Neuropsychopharmacol Biol Psychiatry 25 (2001) 1513-1521
51. Roher A.E., Esh C., Kokjohn T.A., Kalback W., Luehrs D.C., Seward J.D., et al. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 23 (2003) 2055-2062
52. Roher A.E., Esh C., Rahman A., Kokjohn T.A., and Beach T.G. Atherosclerosis of cerebral arteries in Alzheimer disease. Stroke 35 Suppl 1 (2004) 2623-2627
53. Rosen W.G., Mohs R.C., and Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatry 141 (1984) 1356-1364
54. Selhub J., Jacques P.E., Bostom A.G., D'Agostino R.B., Wilson P.W., Belanger A.J., et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332 (1995) 286-291
55. Selley M.L. Increased homocysteine and decreased adenosine formation in Alzheimer's disease. Neurol Res 26 (2004) 554-557
56. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 14 (2002) 476-483
57. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., and Markesbery W.R. Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study. JAMA 277 (1997) 813-817
58. Soderberg M., Edlund C., Kristensson K., and Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26 (1991) 421-425
59. Struys E.A., Jansen E.E.W., de Meer K., and Jakobs C. Determination of S-adenosylmethionine and S-adenosylhomocysteine in plasma and cerebrospinal fluid by stable-isotope dilution mass spectrometry. Clin Chem 46 (2000) 1650-1656
60. Sutton-Tyrrell K., Bostom A., Selhub J., and Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 96 (1997) 1745-1749
61. Vance D.E., Walkley C.J., and Cui Z. Phosphatidylethanolamine N-methyltransferase from liver. Biochim Biophys Acta 1348 (1997) 142-150
62. Wang W.Q., and Gustafson A. Erythrocyte lipid extraction in alcohol-chloroform systems: a comparative study. Acta Chem Scand 48 (1994) 753-758
63. Watkins S.M., Zhu X., and Zeisel S.H. Phosphatidylethanolamine-N-methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice. J Nutr 133 (2003) 3386-3391
64. Yao J.K., Leonard S., and Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 42 (2000) 7-17
65. Yi P., Melnyk S., Pogribna M., Pogribny I.P., Hine J., and James S.J. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 275 (2000) 29318-29323